Thursday, October 28, 2021

Janssen seeks EU approval for first CAR-T therapy cilta-cel

Johnson & Johnson’s (J&J) pharma division Janssen has filed its first CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA), seeking approval for the treatment of patients with relapsed/refractory multiple myeloma.

The marketing authorisation application (MAA) is supported by results from Janssen’s ongoing Phase Ib/II CARTITUDE-1 study, which is investigating the safety and efficacy of cilta-cel.

Results from this study were recently presented at the virtual American Society of Hematology (ASH) annual meeting, showing ‘very high’ overall response rates (ORR).

In the results, 97% of patients achieved a response, with 67% achieving a stringent complete response (sCR) at a median follow-up of 12.4 months.

Meanwhile, median progression-free survival (PFS) was not reached at the median follow-up, with the 12-month PFS rate found to be 77% and a 12-month overall survival rate of 89%.

The trial included 97 patients treated with cilta-cel who received a median of six prior lines of therapy, with 88% being triple-refractory and 99% refractory to the last line of therapy.

“Despite advances in the treatment of multiple myeloma, there remains a high unmet need, especially for patients whose disease continues to progress,” said Peter Lebowitz, global therapeutic area head, oncology, Janssen research & development.

“Through our collaboration with Legend Biotech, we continue to expedite the development of cilta-cel with a focus and priority on the patients who may benefit from this novel immunotherapy in the future,” he added.

In 2017, Janssen entered into a license and collaboration agreement with Legend Biotech to develop and commercialise cilta-cel, which was followed by the initiation of the CARTITUDE-1 trial in May 2018.

The EMA previously granted cilta-cel a Priority Medicines (PRIME) designation in 2019, while the European Commission granted the CAR-T therapy an orphan designation in 2020.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...